Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 8, 2016, Pages 915-927

  Pineton de Chambrun, Guillaume ^a   Blanc, Pierre ^a   Peyrin Biroulet, Laurent ^b  

^a UNIV MONTPELLIER   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

clinical remission; Crohn s disease; deep remission; endoscopic remission; inflammatory bowel disease; mucosal healing; treatment goals; ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; GOLIMUMAB; INFLIXIMAB; MESALAZINE; METHOTREXATE; VEDOLIZUMAB; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

COHORT ANALYSIS; COLON RESECTION; COLONOSCOPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENDOSCOPY; FEASIBILITY STUDY; HEALING; HOSPITALIZATION; HUMAN; MUCOSAL HEALING; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; TREATMENT OUTCOME; ULCERATIVE COLITIS; COLON; DRUG EFFECT; INTESTINE MUCOSA; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR; WOUND HEALING;

ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84963850079     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1174064     Document Type: Review

References (107)

1. D.K.Podolsky Inflammatory bowel disease. N Engl J Med. 2002 Aug 8;347(6):417–429.
2. G.Rogler, S.Vavricka, A.Schoepfer, et al. Mucosal healing and deep remission: what does it mean? World J Gastroenterol. 2013 Nov 21;19(43):7552–7560.
3. C.Zallot, L.Peyrin-Biroulet. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013 Mar;15(3):315.
4. G.Bouguen, L.Peyrin-Biroulet. Surgery for adult Crohn’s disease: what is the actual risk? Gut. 2011 Sep;60(9):1178–1181.
5. J.Filippi, P.B.Allen, X.Hebuterne, et al. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Current Drug Targets. 2011 Sep;12(10):1440–1447.
6. R.Khanna, B.Bressler, B.G.Levesque, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet. 2015 Nov 7;386(10006):1825–1834.
7. G.Pineton de Chambrun, L.Peyrin-Biroulet, M.Lemann, et al Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):15–29.
8. K.W.Schroeder, W.J.Tremaine, D.M.Ilstrup. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625–1629.
9. L.Peyrin-Biroulet, W.Reinisch, J.F.Colombel, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut. 2014 Jan;63(1):88–95.
10. G.R.Greenberg, B.G.Feagan, F.Martin, et al. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Canadian inflammatory bowel disease study group. Gastroenterology. 1996 Jan;110(1):45–51.
11. P.Munkholm, E.Langholz, M.Davidsen, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995 Jul;30(7):699–706.
12. W.J.Sandborn. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008 Nov;135(5):1442–1447.
13. I.D.Arnott, D.Watts, S.Ghosh. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn’s disease? Aliment Pharmacol Ther. 2002 May;16(5):857–867.
14. S.Kane. Endoscopic healing should be a goal for everyone with ulcerative colitis. Inflamm Bowel Dis. 2008 Nov 4. doi:10.1002/ibd.20779. [Epub ahead of print].
15. G.R.Lichtenstein, P.Rutgeerts. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010 Feb;16(2):338–346.
16. P.Rutgeerts, S.Vermeire, G.Van Assche. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007 Apr;56(4):453–455.
17. L.Peyrin-Biroulet, M.Ferrante, F.Magro, et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011 Oct;5(5):477–483.
18. J.F.Colombel, E.Louis, L.Peyrin-Biroulet, et al. Deep remission: a new concept? Dig Diseases. 2012;30(Suppl 3):107–111.
19. W.Afif, J.A.Leighton, S.B.Hanauer, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Apr 30;15:1302–1307.
20. P.B.Allen, L.Peyrin-Biroulet. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013 Jul;29(4):397–404.
21. C.Gower-Rousseau, H.Sarter, G.Savoye, et al. Validation of the inflammatory bowel disease disability index in a population-based cohort. Gut. 2015 Dec 8. doi:10.1136/gutjnl-2015-310151. [Epub ahead of print]
22. B.Pariente, J.Y.Mary, S.Danese, et al. Development of the Lemann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology. 2015 Jan;148(1):52–63e3.
23. L.Peyrin-Biroulet, A.Cieza, W.J.Sandborn, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012 Feb;61(2):241–247.
24. J.F.Colombel, P.J.Rutgeerts, W.J.Sandborn, et al. Adalimumab induces deep remission in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014 Mar;12(3):414–22e5.•• This 2014 subsequent analysis of the EXTENT study investigated adalimumab for inducing and maintaining deep remission at week 12 and 52. This study demonstrated that no patient achieving early deep remission were hospitalized or underwent a CD-related surgery.
25. L.Peyrin-Biroulet. Clinical remission as defined by the Mayo Score: do we deceive ourselves? Inflamm Bowel Dis. 2015 Jan;21(1):E2–E3.
26. B.G.Levesque, W.J.Sandborn, J.Ruel, et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015 Jan;148(1):37–51e1.
27. L.Peyrin-Biroulet, W.Sandborn, B.E.Sands, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015 Sep;110(9):1324–1338.
28. L.Peyrin-Biroulet. Deep remission in Crohn’s disease: is it the end of the placebo effect? Clin Gastroenterol Hepatol. 2014 Feb;12(2):347.
29. R.Sostegni, M.Daperno, N.Scaglione, et al. Review article: Crohn’s disease: monitoring disease activity. Aliment Pharmacol Ther. 2003 Jun;17(Suppl 2):11–17.
30. D.S.Fefferman, R.J.Farrell. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol. 2005 Jan;3(1):11–24.
31. G.D’Haens, W.J.Sandborn, B.G.Feagan, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb;132(2):763–786.
32. W.J.Sandborn, B.G.Feagan, S.B.Hanauer, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002 Feb;122(2):512–530.
33. J.Y.Mary, R.Modigliani. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989 Jul;30(7):983–989.
34. M.Daperno, G.D’Haens, G.Van Assche, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004 Oct;60(4):505–512.
35. S.P.Travis, D.Schnell, P.Krzeski, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012 Apr;61(4):535–542.
36. S.P.Travis, D.Schnell, P.Krzeski, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov;145(5):987–995.
37. J.F.Colombel, W.J.Sandborn, W.Reinisch, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010 Apr 15;362(15):1383–1395.
38. S.B.Hanauer, B.G.Feagan, G.R.Lichtenstein, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002 May 4;359(9317):1541–1549.
39. P.Rutgeerts, G.Van Assche, W.J.Sandborn, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012 May;142(5):1102-11e2.•• This study proposed for the first time a definition of deep remission defined as CDAI <150 and complete MH (absence of mucosal ulcerations).
40. L.Vuitton, P.Marteau, W.J.Sandborn, et al. IOIBD technical review on endoscopic indices for Crohn’s disease clinical trials. Gut. 2015 Sep 9. doi: 10.1136/gutjnl-2015-309903. [Epub ahead of print].
41. J.F.Colombel, P.Rutgeerts, W.Reinisch, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct;141(4):1194–1201.
42. P.Molander, T.Sipponen, H.Kemppainen, et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha-blocking agents in IBD. J Crohns Colitis. 2013 Oct;7(9):730–735.•• This study investigates deep remission in a hospital-based cohort in both CD and UC. Deep remission is defined as no clinical symptoms with Mayo endoscopic subscore 0–1 in UC and no clinical symptoms with SES-CD 0–2. In this study, 62% and 43% of UC and CD patients, respectively, achieved deep remission with anti-TNF-α antibodies.
43. A.Dignass, S.Stoynov, A.E.Dorofeyev, et al. Once versus three times daily dosing of oral budesonide for active Crohn’s disease: a double-blind, double-dummy, randomised trial. J Crohns Colitis. 2014 Sep;8(9):970–980.• This multicenter double-blind, randomized, controlled study investigated deep remission defined as CDAI <150 and SES-CD = 0 in mild-to-moderately active ileocolonic CD.
44. J.F.Colombel, W.Reinisch, G.J.Mantzaris, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn’s disease - a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015 Apr;41(8):734–746.•• This 2015 post hoc analysis of the SONIC trial evaluated deep remission (clinical remission + MH) at week 26 in a subgroup of patients with Crohn’s disease activity index (CDAI) scores, CRP, and endoscopic data available at baseline and week 26. Overall, independent of trea tment allocation, deep remission was achieved by 38% of the patients.
45. S.B.Hanauer, W.J.Sandborn, C.Dallaire, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol. 2007 Dec;21(12):827–834.
46. S.B.Hanauer, W.J.Sandborn, A.Kornbluth, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov;100(11):2478–2485.
47. L.Peyrin-Biroulet, F.Gonzalez, L.Dubuquoy, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn’s disease. Gut. 2012 Jan;61(1):78–85.
48. L.S.Kiss, T.Szamosi, T.Molnar, et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease. Aliment Pharmacol Ther. 2011 Oct;34(8):911–922.
49. G.D’Haens, M.Noman, F.Baert, et al. Endoscopic healing after infliximab treatment for Crohn’s disease provides a longer time to relapse. Gastroenterology. 2002;122:A–618.
50. J.Guardiola, T.Lobaton, L.Rodriguez-Alonso, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014 Nov;12(11):1865–1870.
51. I.Ordas, J.Rimola, S.Rodriguez, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology. 2014 Feb;146(2):374–382 e1.
52. A.Bressenot, J.Salleron, C.Bastien, et al. Comparing histological activity indexes in UC. Gut. 2015 Sep;64(9):1412–1418.
53. A.Marchal-Bressenot, J.Salleron, C.Boulagnon-Rombi, et al. Development and validation of the Nancy histological index for UC. Gut. 2015 Oct 13. doi:10.1136/gutjnl-2015-310187. [Epub ahead of print].
54. M.Bortlik, D.Duricova, N.Machkova, et al. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scand J Gastroenterol. 2016;51(2):196–202.
55. E.Louis, J.Y.Mary, G.Vernier-Massouille, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012 Jan;142(1):63–70e5; quiz e31.
56. P.Molander, M.Farkkila, K.Salminen, et al. Outcome after discontinuation of TNFalpha-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis. 2014 Jun;20(6):1021–1028.
57. S.S.Buhl, C.Steenholdt, J.Brynskov, et al. Discontinuation of infliximab therapy in patients with Crohn’s disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. BMJ Open. 2014;4(12):e005887.
58. G.D’Haens, K.Geboes, E.Ponette, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology. 1997 May;112(5):1475–1481.
59. G.D’Haens, K.Geboes, P.Rutgeerts. Endoscopic and histologic healing of Crohn’s (ileo-) colitis with azathioprine. Gastrointest Endosc. 1999 Nov;50(5):667–671.
60. W.J.Sandborn, O.E.Van, B.J.Zins, et al. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn’s disease. Gastroenterology. 1995 Dec;109(6):1808–1817.
61. G.J.Mantzaris, A.Christidou, M.Sfakianakis, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn’s disease. Inflamm Bowel Dis. 2009 Mar;15(3):375–382.
62. B.G.Feagan, J.Rochon, R.N.Fedorak, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s study group investigators. N Engl J Med. 1995 Feb 2;332(5):292–297.
63. O.A.Paoluzi, R.Pica, A.Marcheggiano, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther. 2002 Oct;16(10):1751–1759.
64. R.A.Kozarek, D.J.Patterson, M.D.Gelfand, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989 Mar 1;110(5):353–356.
65. M.Manosa, J.E.Naves, C.Leal, et al. Does methotrexate induce mucosal healing in Crohn’s disease? Inflamm Bowel Dis. 2010 Mar;16(3):377–378.
66. B.G.Feagan, P.Rutgeerts, B.E.Sands, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699–710.•• This randomized, double-blind, placebo-controlled trial demonstrated that induction treatment with vedolizumab 300 mg at week 0 and 2 for UC patients resulted in MH at week 6 (Mayo endoscopic subscore of 0 or 1) in 41% of patients compared to 25% of patients treated with placebo.
67. P.Rutgeerts, R.H.Diamond, M.Bala, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc. 2006 Mar;63(3):433–442; quiz 64.
68. P.Rutgeerts, B.G.Feagan, G.R.Lichtenstein, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004 Feb;126(2):402–413.
69. J.Colombel, P.Rutgeerts, W.Reinisch, et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naive to immunomodulators and biological therapy. Gut. 2008;57(suppl II):A-1.
70. X.Hebuterne, M.Lemann, Y.Bouhnik, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut. 2013 Feb;62(2):201–208.
71. J.R.Green, J.C.Mansfield, J.A.Gibson, et al. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther. 2002 Jan;16(1):61–68.
72. M.A.Kamm, W.J.Sandborn, M.Gassull, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007 Jan;132(1):66–75; quiz 432–433.
73. W.Kruis, G.Kiudelis, I.Racz, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009 Feb;58(2):233–240.
74. G.R.Lichtenstein, P.Rutgeerts. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010 Feb;16(2):338–346.
75. H.Malchow, B.Gertz. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Aliment Pharmacol Ther. 2002 Mar;16(3):415–423.
76. J.C.Mansfield, M.H.Giaffer, P.A.Cann, et al. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther. 2002 Jan;16(1):69–77.
77. M.Vecchi, G.Meucci, P.Gionchetti, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther. 2001 Feb;15(2):251–256.
78. J.K.Marshall, E.J.Irvine. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997 Jun;40(6):775–781.
79. V.Gross, S.Bar-Meir, A.Lavy, et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther. 2006 Jan 15;23(2):303–312.
80. M.Regueiro, E.V.LoftusJr., A.H.Steinhart, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006 Oct;12(10):979–994.
81. S.C.Truelove, L.J.Witts. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041–1048.
82. S.C.Truelove, L.J.Witts. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954 Aug 14;2(4884):375–378.
83. M.Barreiro, A.Lorenzo, J.Mera, et al. Prospective, open pilot study for evaluating the clinical efficacy and mucosal healing rate of infliximab in steroid-dependent ulcerative colitis. Gastroenterology. 2008;134(4):A-667.
84. R.Panaccione, S.Ghosh, S.Middleton, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014 Feb;146(2):392–400e3.
85. P.Rutgeerts, W.J.Sandborn, B.G.Feagan, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462–2476.
86. W.J.Sandborn, G.Van Assche, W.Reinisch, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb;142(2):257–65e1–3.•• This multicenter, randomized, double-blind, placebo-controlled trial investigated the efficacy of golimumab for the treatment of moderate-to-severe active UC. Induction therapy with golimumab SC injections 200/100 mg and 400/200 mg at weeks 0 and 2 resulted in MH (Mayo endoscopy subscore of 0 or 1) in 42% and 45% of patients at week 6, respectively, compared to 28% of patients receiving placebo.
87. W.J.Sandborn, B.G.Feagan, C.Marano, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):85–95;quiz e14–e15.
88. W.J.Sandborn, B.G.Feagan, C.Marano, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):96–109e1.
89. G.D’Haens, F.Baert, G.van Assche, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008 Feb 23;371(9613):660–667.
90. F.J.Baert, L.Moortgat, G.Van Assche, et al Mucosal healing predicts sustained clinical remission in early Crohn’s disease. Gastroenterology. 2008;134(4,suppl 1):A-640.
91. L.Libier, M.Collins, D.Koriche, et al. Evaluation and long-term benefit of mucosal healing in Crohn’s disease patients treated with infliximab. Gastroenterology. 2015;148(4,Suppl 1):S-450.
92. R.Wright, S.R.Truelove. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis. 1966 Nov;11(11):847–857.
93. W.J.Sandborn, J.F.Colombel, W.Reinisch, et al. Infliximab induces and maintains mucosal healing in ulcerative colitis patients: the ACT trials. Am J Gastroenterol. 2005;100:S310.
94. M.Allez, M.Lemann, J.Bonnet, et al. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol. 2002 Apr;97(4):947–953.
95. F.Schnitzler, H.Fidder, M.Ferrante, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis. 2009 Sep;15(9):1295–1301.• This trial evaluated healing as a predictor of better outcome in Crohn’s disease. Complete but also partial healing induced by long-term maintenance treatment was associated with a lower need for major abdominal surgeries.
96. M.Ferrante, S.Vermeire, H.Fidder, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219–225.
97. K.F.Froslie, J.Jahnsen, B.A.Moum, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007 Aug;133(2):412–422.
98. I.C.Solberg, I.Lygren, J.Jahnsen, et al. Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease. Gut. 2008;57(suppl II):A–15.
99. A.Oussalah, L.Evesque, D.Laharie, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010 Dec;105(12):2617–2625.
100. D.Laharie, J.Filippi, X.Roblin, et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther. 2013 May;37(10):998–1004.
101. G.Meucci, R.Fasoli, S.Saibeni, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis. 2012 Jun;18(6):1006–1010.•• This prospective, multicenter study showed that persistence of endoscopic activity in ulcerative colitis is a very strong predictor of early relapse. Endoscopic remission was defined as normal-appearing mucosa or only mild redness and/or friability, without either ulcers or erosions.
102. S.A.Riley, V.Mani, M.J.Goodman, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991 Feb;32(2):174–178.
103. A.Bitton, M.A.Peppercorn, D.A.Antonioli, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001 Jan;120(1):13–20.
104. R.B.Gupta, N.Harpaz, S.Itzkowitz, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007 Oct;133(4):1099–105; quiz 340–341.
105. M.Karin. Nuclear factor-kappaB in cancer development and progression. Nature. 2006 May 25;441(7092):431–436.
106. M.D.Rutter, B.P.Saunders, K.H.Wilkinson, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004 Dec;53(12):1813–1816.
107. M.Rutter, B.Saunders, K.Wilkinson, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004 Feb;126(2):451–459.